Clinical Advisors


Juan.png

Dr. Juan Frias, MD

Chair, Clinical Advisory Board

Dr. Juan Frias is Chair of the Clinical Advisory Board and has 25 years of experience in the diabetes industry. He is also currently President and Principal Investigator of the National Research Institute in Los Angeles, CA.

After serving five years as a General Medical Officer in the US Navy, he completed his training in Internal Medicine at Vanderbilt University and the University of Tennessee, and his Fellowship in Endocrinology, Diabetes and Metabolism at the University of California, San Diego.

Dr. Frías has held leadership positions in Clinical and Medical Affairs at Eli Lilly, Amylin Pharmaceuticals, Pfizer, and Johnson and Johnson, where he served as Chief Medical Officer and Global Vice President of Clinical and Medical Affairs, Diabetes Care.

He has held academic positions at the University of Colorado Health Sciences Center, Barbara Davis Center for Diabetes, and the University of California San Diego School of Medicine, where he is currently on the clinical faculty. Dr. Frías has been involved in diabetes and metabolism-related research for over 20 years and has authored numerous publications in this field.

Dr. Frias is an endocrinologist with a BA from University of Florida, an MD from Vanderbilt University, and he completed his fellowship training at University of California San Diego.

 

Business Advisors


Matt Zames Business Advisory Board

Matt Zames

Business Advisor

Matt Zames has more than 20 years of experience in leadership positions across financial services. Currently, he serves as President of Cerberus Capital Management where he has broad responsibilities across the Firm’s global businesses and leads a number of strategic investing and operating initiatives, including overseeing all investments in the financial services industry.

Prior to this, Matt was the Chief Operating Officer of J.P. Morgan Chase & Co. and served on the Operating Committee. In his role as COO, his responsibilities included the firm's Chief Investment Office (CIO), the Oversight and Control Group, Treasury & Funding, Mortgage Banking Capital Markets, One Equity Partners, Corporate Strategy, Regulatory Affairs, Global Technology and Operations, Real Estate, Procurement, Security & Safety, General Services and Military & Veteran Affairs. Mr. Zames was co-COO from July 2012 until April of 2013 when he assumed the full COO position. Previously, he was Chief Investment Officer of J.P. Morgan Chase.

Prior to joining the corporate sector in 2012, Mr. Zames held a series of senior roles in the firm's Investment Bank. Most recently, he was co-head of Global Fixed Income for J.P. Morgan's Investment Bank and head of Chase's Mortgage Banking Capital Markets. Before that, he managed several leading Markets businesses, including Rates, Foreign Exchange, Public Finance, Securitized Products Group, and the Tax-Exempt Capital Markets business.

Before joining J.P. Morgan in 2004, Mr. Zames worked at Credit Suisse, where he was co-head of Global Dollar Interest Rate Trading, a member of the Fixed Income Operating Committee, and the Credit Suisse First Boston Management Council.

Mr. Zames is a former member and chairman of the U.S. Treasury Department's Treasury Borrowing Advisory Committee. He is also a former member of the Federal Reserve Bank of New York's Treasury Market Practices Group. Additionally, he is a member of The Economic Club of NY, and a member of the Council on Foreign Relations. He is on the MIT Sloan Finance Group Advisory Board, on the Board of Directors of Business Executives for National Security (BENS), on the Board of Directors of the Marine Corps-Law Enforcement Foundation, on the Board of Directors of Guiding Eyes for the Blind and Board Co-Chairman of the Institute for Veterans and Military Families at Syracuse University.

He graduated from the Massachusetts Institute of Technology in 1993. He lives in New Jersey with his wife and children.


VP of R&D

Hari Mahadevan

Business Advisor

Over the past three decades, Hari has served in a variety of leadership roles in what he terms “his meandering career” across the Life Sciences.

Today, as the founder of Mahadevan Consulting, LLC, he serves either as an adviser or on the Board of Directors/Advisory Board of both public and private equity-owned organizations ranging in valuation from $100+ million to the Fortune 50. Hari also serves, in an ad-hoc Board member role, to an intentionally diverse set of CEOs/Presidents as a business advisor/thought partner on issues of growth strategy, operational execution, and executive alignment, all designed to drive profitable enterprise growth.

Hari is also an adjunct professor at the Wharton School, teaching MBA classes ranging from Commercialization in the Life Sciences to Healthcare Data & Analytics.

Hari also served for nine years as an Executive Officer at Rosetta, where he founded and grew its Healthcare Vertical – Rosetta’s largest and most profitable business – as well as its highly differentiated Consulting Practice. His Partners and he sold Rosetta in 2011 to the Publicis Groupe for $575 million. Prior to Rosetta, Hari spent over five years as a strategy consulting professional at McKinsey & Company. He also held technical and managerial roles at Celgene, Merck, and the NASA Glenn Research Center.

Hari earned his Bachelor of Technology from the University of Madras, a PhD in Chemical Engineering from North Carolina State University, and his MBA in Healthcare Management from the Wharton School of Business.